Treatment Options for Metastatic Prostate Cancer

Discusses the treatment options for denovo metastatic castrate sensitive prostate cancer, including the criteria for high and low volume disease. Also covers the first-line options for metastatic castrate resistant prostate cancer and the use of oral anti-androgen medications, upfront chemotherapy with docetaxel, radium-223 for bone disease, and cabazitaxel for asymptomatic M1 CRPC.